Текст книги "Респираторная медицина. Руководство (в 2-х томах)"
Автор книги: А. Чучалин
Жанр:
Медицина
сообщить о нарушении
Текущая страница: 79 (всего у книги 191 страниц)
67.Custovic A., Smith A., Woodcock A. Indoor allergens are a primary cause of asthma // Eur. Respir. Rev. – 1998. – V. 8, N 53. – P.155-158.
68.Zejda J.E., Skiba M., Orawiec A. et al. Respiratory symptoms in children of Upper Silesia, Poland cross-sectional study in two towns of different air pollution levels // Eur. J. Epidemiool. – 1996. – V. 12, N 1. – P. 115-120.
69.Рылеева И.В., Балаболкин И.И., Дрынов Г.И. Значение сенсибилизации к аэроаллерге-нам жилищ в развитии бронхиальной астмы у детей (обзор литературы) // Рос. вест. пе-ринатол. и педиатр. – 1994. – 4. – С. 18-20.
70.Kang B.C., Johnson J., Veres-Thorner C. Atopic profile of inner-city asthma with a compa-rative analysis on the cockroach-sensitive and ragweed-sensitive subgroups // J. Allergy Clin.Immunol. – 1993. – V. 92, N 6. – P. 802-811.
71.Sastre J., Ibanez M.D., Lombardero M. et al. Allergy to cockroaches in patients with asthma and rhinitis in an urban area Madrid // Allergy. – 1996. – V. 51, N 8. – P. 582-586.
72.Гервазиева В.Б., Жирова С.Н., Вострокнутова Т.М. Выявление сенсибилизации к ком-понентам домашней пыли у больных бронхиальной астмой // Шестой национальный конгресс по болезням органов дыхания. Сборник Резюме. – Новосибирск, 1996.– С. 17.
73.Емельянов А.В. Причины, вызывающие воспаление. Аллергены // Механизмы воспаления бронхов и легких и противовоспалительная терапия / под ред. Г. Б. Федосеева. – СПб., Нордмед-Издат. – 1998. – С. 94-103.
74.Желтикова Т.М., Антропова А.Б., Петрова-Никитина А.Д. Экология жилых помещений и аллергия // Аллергология. – 2004. – 3. – С.37-39
75.Шнипас П.А., Золубас М.И. Аллергенные плесневые грибки в окружающей среде и сенсибилизация ими у больных бронхиальной астмой // Бронхиальная астма. – Л., 1989. – С. 55-58.
76.Halonen M.,. Stern D.A,. Wright A.L et al. Alternaria as a major allergen for asthma in chil-dren raised in a desert environment // Am. J. Respir. Crit. Care. Med. – 1997. – V. 155, N 4. – P. 1356-1361.
77.Malling H.J., Dreborg S., Weeke B. Diagnosis and immunotherapy of mould allergy. III. Di-agnosis of Cladosporium allergy by means of symptom score, bronchial provocation test, skin prick test, RAST, CRIE and histamine release // Allergy. – 1986. – V. 41, N 1. – P. 57-67.
78.Балаболкин И.И. Бронхиальная астма // Аллергические болезни у детей / Под ред. М.Я. Студеникина, И.И. Балаболкина. – М., Медицина. – 1998. – С. 188-212.
79.Liard R., Neukirch C., Bousquet J. et al. Sensitization to Alternaria Alternata and severe asthma: Preliminary results in a population study // Eur. Respir. Rev. – 1997. – V. 10, Suppl. 25. – 143 s.
80.Остроумов А.И. Амброзийный поллиноз: Дис. ... докт. мед. наук. – Краснодар, 1982. – 296 с.
81.Астафьева Н.Г., Горячкина Л.А. Поллиноз – пыльцевая аллергия //Аллергология. – 1998. – 2. – С. 34-40
82.D’Amato G., Liccardi G. Pollen-related allergy in the European Mediterranean area // Clin. Exp. Allergy. – 1994. – V. 24. – P. 210-219.
83.Воржева И.И. Поллинозы в Восточной Сибири: клинико-аллергологическая характеристика и эффективность лечения // Актуальные проблемы клинической медицины. Иркутск. – 1999. – С. 30-39.
84.Отчет о международном Консенсусе по диагностике и лечению ринита // Российская ринология. – 1996. – 4. – С. 1-47.
85.WHO Position Paper Allergen immunotherapy : therapeutic vaccines for allergic diseases // Allergy. – 1998. – Supplement. – V. 53, N 44. / G. Ed. J. Bousquet, R.F. Lockey, H.J. Malling.
86.Хаитов Р.М., Пинегин Б.В., Истамов Х.И. Экологическая иммунология. – М., 1995.– 218 с.
87.Leikauf G.D., Kline S., Albert R.E. et al. Evaluation of a possible association of urban air toxics and asthma. // Environ. Health Perspect. – 1995. – Vol.103, Suppl. 6. – P.253 – 271.
88.Martin B.W., Ackermann-Liebrich U., Leuenberger P. et al. SAPALDIA: methods and participation in the cross-sectional part of the Swiss Study on Air Pollution and Lung Diseases in Adults. // Sozial – und Praventivmedizin. – 1997. – Bd.42, 2. – S.64 – 84.
89.Pauli G., Kopferichmitt M.Ch., Spirlet F., Charpin D. Air pollutants and allergic sensitisation // Genetics to Quality of Life /Ed. P. Chanez, J. Bousguet, F.B. Michel, P. Godard. – Seattle: Hogrefe Huber Publ., 1996. – P.80 – 90.
90.Devalia J.L., Rusznak C., Wang J., Davies R.L. Pollution – allergen interactions: challenge studies in man. // Eur. Respir. Rev. – 1998. – Vol.8, 53. – P.175 – 178.
91.Department of Health Advisory Group on the Medical Aspect of Air Pollution Episodes. Second Report. Sulphur dioxide, acid aerosols and particulates. London: HMSO; 1992
92.Paun G, Dutu St. Prevalence of Respiratory Symptoms, Asthma Bronchiale and Chronic Bronchitis in an Industrial Environment with High Air Pollution. // Eur. Respir. J. – 1996. – Vol.9, Suppl.23. – P.353s.
93.Wardlaw A.J. The role of air pollution in asthma. // Exp. Allergy. – 1993. – Vol.23. – P.81 – 96.
94.Emberlin J. The effects of air pollution on allergenic pollen. // Ibid. – 1998. – Vol.8, 53. – P.164 – 167.
95.Pierson W.E., Koenig J.Q. Respiratory effects of air pollution on allergic disease. // S. Allergy Clin. Immunol. – 1992. Vol. 90. – P.557 – 566.
96.Folinsbee L.J. Does nitrogen dioxide exposure increase airways responsiveness? // Toxicol. Industrial Health. – 1992. – Vol.8. – P.273 – 283.
97.Sunyer J. Nitrogen dioxide: an unimportant cause of health effects? // Eur. Respir. Rev. 1998. – Vol.8, 53. – P.139 – 140.
98.Department of Health Advisory Group on the Medical Aspect of Air Pollution Episodes. Second Report. Sulphur dioxide, acid aerosols and particulates. London: HMSO; 1992
99.Sandstrom T., Blomberg A., Helleday R. Air pollution-allergy interaction: experiences
from animal studies //Eur. Reespir. Rev. – 1998. – V. 8, N 53. – P. 168-174 .
100.Devalia J.L., Rusznak C., Herdman M.J. et al. Effect of nitrogen dioxide and sulphur dioxide on the airway responses of mild in asthmatic patients to allergen inhalation // Lancet. – 1994. – V.344. – P. 1668-1671.
101.Tunnicliffe W.C., Burge P.C., Ayers J.G. Effect of domestic concentrations of nitrogen dioxide on airway responses to inhaled allergen in asthmatic patients // Lancet. – 1994. – V. 344. – P. 1733 – 1736.
102.Wang J., Devalia J.L., Duddle J.M. et al. The effect оf exposure for six hours to nitrogen dioxide on early phase nasal response to allergen challenge in patients with a history of seasonal allergic rhinitis // J. Allergy Clin. Immunol. – 1995. – V. 96, N 2. – P. 669-676.
103.Meza C., Gershwin M.E. Why is asthma becoming more of a problem? // Curr. Opin. Pulm. Med. – 1997. – Vol.3, 1. – P.6 – 9.
104.Campbell M.J., Cogman G.R., Holgate S.T., Johnston S.L. Age specific trends in asthma mortality in England and Wales, 1983 – 95: results of an observational study // Br. Med. J. 1997. – Vol.314, 7092. – P.1439 – 1441.
105.Mormile F., Chiappini F., Feola G., Ciappi G. Deaths from asthma in Italy (1974 – 1988): is there a relationship with changing pharmacological approaches? // J. Clin. Epidem. – 1996. – Vol.49, 12. – P.1459 – 1466.
106.Alves J., Hespanhol V., Magalhaes A. et al. Prevalence of asthma in the city of Porto // Ac-ta Med. Port. – 1994. – V. 7, N 1. – P. 21-24.
107.Spitzer W.O. The use of beta-agonists and the risk of death and near death from asthma. // N. Engl. J. Med. – 1992. – Vol.326. – P.501 – 506.
108.Buist S. Asthma mortality: what have we learned? // J. Allergy Clin. Immunol. – 1989. – Vol.84. – P.275 – 283.
109.Bai TR, Mak C, Barnes PJ: A comparison of beta-adrenergic receptors and in vitro relaxant responses to isoproterenol in asthmatic airway smooth muscle. Am J Respir Cell Mol Biol 6:647-651, 1992.
110.Simpson BM, Custovic A, Simpson A, et al: NAC Manchester Asthma and Allergy Study (NACMAAS): Risk factors for asthma and allergic disorders in adults. Clin Exp Allergy 31:391-399, 2001.
111.Lundback B: Epidemiology of rhinitis and asthma. Clin Exp Allergy 28(Suppl 2):3-10, 1998.
112.Xu B, Pekkanen J, Laitinen J, Jarvelin MR: Body build from birth to adulthood and risk of asthma. Eur J Public Health 12:166-170, 2002.
113.Arif AA, Delclos GL, Lee ES, et al: Prevalence and risk factors of asthma and wheezing among US adults: An analysis of the NHANES III data. Eur Respir J 21:827-833, 2003.
114.Diaz-Sanchez D, Proietti L, Polosa R: Diesel fumes and the rising prevalence of atopy: An urban legend? Curr Allergy Asthma Rep 3:146-152, 2003.
115.Sporik R, Holgate ST, Platts-Mills TAE, Cogswell JJ: Exposure to house-dust mite allergen (Der p1) and the development of asthma in childhood. N Engl J Med 323:502-507, 1990.
116.Sears MR, Herbison GP, Holdaway MD, et al: The relative risks of sensitivity to grass pollen, house dust mite and cat dander in the development of childhood asthma. Clin Exp Allergy 19:419-424, 1989.
117.Peat JK, Tovey E, Mellis CM, et al: Importance of house dust mite and Alternaria allergens in childhood asthma: An epidemiological study in two climatic regions of Australia. Clin Exp Allergy 23:812-820, 1993.
118.Kmietowicz Z: Cockroaches blamed for high asthma rates. BMJ 314:1437, 1997.
119.Platts-Mills TAE, Sporic R, Ingram JM, Honsinger R: Dog and cat allergens and asthma among school children in Los Alamos, New Mexico, USA: Altitude 7200 feet. Int Arch Allergy Immunol 107:301-313, 1995.
120.Chan-Yeung M, Manfreda J, Dimich-Ward H, et al: A randomized controlled study on the effectiveness of a multifaceted intervention program in the primary prevention of asthma in high-risk infants. Arch Pediatr Adolesc Med 154:657-663, 2000.
121.Custovic A, Simpson BM, Simpson A, et al: Effect of environmental manipulation in pregnancy and early life on respiratory symptoms and atopy during first year of life: A randomised trial. Lancet 358:188-193, 2001.
122.Arshad SH, Bojarskas J, Tsitoura S, et al: Prevention of sensitization to house dust mite by allergen avoidance in school age children: A randomized controlled study. Clin Exp Allergy 32:843-849, 2002.
123.Arshad SH, Bateman B, Matthews SM: Primary prevention of asthma and atopy during childhood by allergen avoidance in infancy: A randomised controlled study. Thorax 58:489-493, 2003.
124.Celedon JC, Litonjua AA, Ryan L, et al: Exposure to cat allergen, maternal history of asthma, and wheezing in first 5 years of life. Lancet 360:781-782, 2002.
125.Ownby DR, Johnson CC, Peterson EL: Exposure to dogs and cats in the first year of life and risk of allergic sensitization at 6 to 7 years of age. JAMA 288:963-972, 2002.
126.Perzanowski MS, Ronmark E, Platts-Mills TA, Lundback B: Effect of cat and dog ownership on sensitization and development of asthma among preteenage children. Am J Respir Crit Care Med 166:696-702, 2002.
127.Huang S-L, Shiao GM, Chou P: Association between body mass index and allergy in teenage girls in Taiwan. Clin Exp Allergy 29:323-329, 1998.
128.Haland G, Carlsen KC, Sandvik L, et al: Reduced lung function at birth and the risk of asthma at 10 years of age. N Engl J Med 355(16):1682-1689, 2006.
129.Ball TM, Castro-Rodriguez JA, Griffith KA, et al: Siblings, day-care attendance, and the risk of asthma and wheezing during childhood. N Engl J Med 343:538-543, 2000.
130.Pattemore PK, Johnston SL, Bardin PG: Viruses as precipitants of asthma symptoms. I Epidemiology. Clin Exp Allergy 22:325-336, 1992.
131.Kraft M, Cassell GH, Henson JE, et al: Detection of Mycoplasma pneumoniae in the airways of adults with chronic asthma. Am J Respir Crit Care Med 158:998-1001, 1998.
132.Klintberg B, Berglund N, Lilja G, et al: Fewer allergic respiratory disorders among farmers' children in a closed birth cohort from Sweden. Eur Respir J 17:1151-1157, 2001.
133.Bjorksten B, Naaber P, Sepp E, Mikelsaar M: The intestinal microflora in allergic Estonian and Swedish 2-year-old children. Clin Exp Allergy 29:342-346, 1999.
134.Kalliomaki M, Salminen S, Poussa T, et al: Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet 361:1869-1871, 2003.
135.Sandford A, Weir T, Pare P: The genetics of asthma. // Am J Respir Crit Care Med – 1996.– Vol 153. – P.1749-1765.
136.Holloway J.W., Beghe B., Holgate S. The genetic basis of atopic asthma // Clin Exp Allergy.-1999.-Vol 29, N 2.-P.1023-1032.
137.Weisch D.G., Meyers D.A., Bleecker E.R. Genetics of asthma // J Allergy Clin Immunol.-1999.-Vol 104.-P.895-901.
138.Global Initiative for Asthma. NHLB/WHO Workshop Report.-National Heart Lung Blood Institute, Publication number 02 – 3659, 2004.
139.Stolley PD: Why the United States was spared an epidemic of death due to asthma. // Am Rev Respir Dis.– 1972.– Vol.105.– P. 883-890.
140.Allen M, Heinzmann A, Noguchi E, et al: Positional cloning of a novel gene influencing asthma from chromosome 2q14. // Nat Genet.– 2003.– Vol.35.– P.258-263.
141.Dizier MH, Besse-Schmittler C, Guilloud-Bataille M, et al: Genome screen for asthma and related phenotypes in the French EGEA study. // Am J Respir Crit Care Med. – 2000.– Vol.162.– P.1812-1818.
142.Hakonarson H, Bjornsdottir US, Halapi E, et al: A major susceptibility gene for asthma maps to chromosome 14q24. // Am J Hum Genet. -2002.– Vol.71.– P.483-491.
143.Yokouchi Y, Nukaga Y, Shibasaki M, et al. Significant evidence for linkage of mite-sensitive childhood asthma to chromosome 5q31-q33 near the interleukin 12 B locus by a genome-wide search in Japanese families. // Genomics.– 2000.– Vol.66.– P.152-160.
144.Blumenthal M.N. The role of genetics in the development of asthma and atopy // Curr Opin Allergy Clin Immunol. 2005.-Vol 5, N2– P.141-145.
145.Ober C., Hoffjan S. Asthma genetics 2006: the long and winding road to gene discovery // Genes and Immunity.-2006.-Vol 7, N 2.-P.95-100.
146.A genome-wide search for asthma susceptibility loci in ethnically diverse populations: The Collaborative Study on the Genetics of Asthma (CSGA). // Nat Genet. – 1997. – Vol. 15. – P. 389-392.
147.O'Donnell CJ, Lindpaintner K, Larson MG, et al: Evidence for association and genetic linkage of the angiotensin-converting enzyme locus with hypertension and blood pressure in men but not women in the Framingham Heart Study. // Circulation. – 1998.– Vol. 97.– P.1766-1772.
148.Cookson WO: 11q and high-affinity IgE receptor in asthma and allergy. // Clin Exp Allergy – 1995.– Vol. 25, Suppl 2, – P.71-73.
149.Barnes KC, Neely JD, Duffy DL, et al: Linkage of asthma and total serum IgE concentration to markers on chromosome 12q: Evidence from Afro-Caribbean and Caucasian populations. // Genomics.– 1996.– Vol. 37.– P.41-50.
150.Nickel R, Wahn U, Hizawa N, et al: Evidence for linkage of chromosome 12q15-q24.1 markers to high total serum IgE concentrations in children of the German Multicenter Allergy Study. // Genomics.– 1997.– Vol. 46.– P.159-162.
151.Postma DS, Bleecker ER, Amelung PJ, et al: Genetic susceptibility to asthma-bronchial hyperresponsiveness coinherited with a major gene for atopy. // N Engl J Med. – 1995.– Vol. 333.– P.894-900.
152.Wang S, Zhao H: Sample size needed to detect gene-gene interactions using association designs. // Am J Epidemiol.– 2003.– Vol. 158.– P. 899-914.
153.Grunig G, Warnock M, Wakil AE, et al: Requirement for IL-13 independently of IL-4 in experimental asthma. // Science.– 1998. – Vol. 282.– P.2261-2263.
154.Symula DJ, Frazer KA, Ueda Y, et al: Functional screening of an asthma QTL in YAC transgenic mice // Nat Genet. – 1999. – Vol. 23.– P.241-244.
155.Hall I.P. Beta-2 adrenergic receptor dysfunction and polymorphism in asthma // UpToDate.-Rose, BD (Ed),Waltham, MA, 2006.
156.Israel E., Drazen J.M., Liggett S.B. et al. The effect of polymorphisms of the beta (2)-adrenergic receptor on the response to regular use of albuterol in asthma // Am J Respir Crit Care Med.-2000.-Vol 162, N 1.-P.75-80.
157.Lipworth B.J., Hall I.P., Aziz I. et al. Beta2-adrenoceptor polymorphism and bronchoprotective sensitivity with regular short– and long-acting beta2-agonist therapy// Clin Sci.-1999.-Vol 96, N 3.-P.253-259.
158.Lima J.J. Treatment Heterogeneity in Asthma : Genetics of Response to Leukotriene Modifiers // Mol Diagn Ther.– 2007.Vol 11, N2.-P.97-104.
159.Busse WW, Lemanske RF, Jr. Asthma// N Engl J Med.– 2001;344(5):350-62.
160.Tattersfield AE, Knox AJ, Britton JR, Hall IP. Asthma// Lancet.-2002.-Vol. 360, N9342.-P. 1313-1322.
161.Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Asthma. From bronchoconstriction to airways inflammation and remodeling// Am J Respir Crit Care Med.– 2000.-Vol 161, N5.-P.1720-45.
162.Cohn L, Elias JA, Chupp GL. Asthma: mechanisms of disease persistence and progression// Annu Rev Immunol.– 2004.-Vol 22.-P.789-815.
163.Galli SJ, Kalesnikoff J, Grimbaldeston MA, Piliponsky AM, Williams CM, Tsai M. Mast cells as "tunable" effector and immunoregulatory cells: recent advances// Annu Rev Immunol.– 2005.-Vol 23.-P.749-86.
164.Robinson DS. The role of the mast cell in asthma: induction of airway hyperresponsiveness by interaction with smooth muscle? // J Allergy Clin Immunol.– 2004.-Vol 114, N1.-P.58-65.
165.Kay AB, Phipps S, Robinson DS. A role for eosinophils in airway remodelling in asthma// Trends Immunol.– 2004.-Vol25, N9.-P.477-482.
166.Larche M, Robinson DS, Kay AB. The role of T lymphocytes in the pathogenesis of asthma// J Allergy Clin Immunol. -2003.-Vol 111, N3.-P.450-463.
167.Akbari O, Faul JL, Hoyte EG, Berry GJ, Wahlstrom J, Kronenberg M, et al. CD4+ invariant T-cell-receptor+ natural killer T cells in bronchial asthma// N Engl J Med.– 2006.– Vol 354, N11.– P.1117-1129.
168.Kuipers H, Lambrecht BN. The interplay of dendritic cells, Th2 cells and regulatory T cells in asthma// Curr Opin Immunol 2004.-Vol16, N6.-P.702-728.
169.Peters-Golden M. The alveolar macrophage: the forgotten cell in asthma// Am J Respir Cell Mol Biol.– 2004.-Vol 31, N1.-P.3-7.
170.Wenzel S. Mechanisms of severe asthma// Clin Exp Allergy.– 2003.-Vol 33, N12.-P.1622-1628.
171.Chung KF. Airway smooth muscle cells: contributing to and regulating airway mucosal inflammation?// Eur Respir J.– 2000.-Vol15, N5.-P.961-8.
172.Groneberg DA, Quarcoo D, Frossard N, Fischer A. Neurogenic mechanisms in bronchial inflammatory diseases// Allergy.– 2004.-Vol 59, N11.-P.1139-52.
173.Miller AL, Lukacs NW. Chemokine receptors: understanding their role in asthmatic disease// Immunol Allergy Clin North Am.– 2004.-Vol 24, N4.-P.667-683.
174.Leff AR. Regulation of leukotrienes in the management of asthma: biology and clinical therapy// Annu Rev Med.– 2001.-Vol52.-P.1-14.
175.Ricciardolo FL, Sterk PJ, Gaston B, Folkerts G. Nitric oxide in health and disease of the respiratory system// Physiol Rev 2004.-Vol 84, N3.-P.731-765.
176.Smith AD, Taylor DR. Is exhaled nitric oxide measurement a useful clinical test in asthma?// Curr Opin Allergy Clin Immunol.– 2005.-Vol. 5, N1.-P.49-56.
177.Barnes PJ. Cytokine modulators as novel therapies for asthma// Annu Rev Pharmacol Toxicol.– 2002.– Vol 42.-P.81-98.
178.James A. Airway remodeling in asthma// Curr Opin Pulm Med 2005.-Vol11, N1.-P.1-6.
179.Vignola AM, Mirabella F, Costanzo G, Di Giorgi R, Gjomarkaj M, Bellia V, et al. Airway remodeling in asthma// Chest.– 2003.-Vol 123, N3 Suppl.-P.417S-22S.
180.Hirst SJ, Martin JG, Bonacci JV, Chan V, Fixman ED, Hamid QA, et al. Proliferative aspects of airway smooth muscle// J Allergy Clin Immunol.– 2004.-Vol114, N2 Suppl.-P. S2-17.
181.Black JL. Asthma–more muscle cells or more muscular cells?// Am J Respir Crit Care Med.– 2004.-Vol 169, N9.-P.980-981.
182.McParland BE, Macklem PT, Pare PD. Airway wall remodeling: friend or foe?// J Appl Physiol.– 2003.-Vol95, N1.-P.426-434.
183.Wang L, McParland BE, Pare PD. The functional consequences of structural changes in the airways: implications for airway hyperresponsiveness in asthma// Chest.– 2003.-Vol 123, N 3 Suppl.-P.356S-62S.
184.Newson R, Strachan D, Archibald E, Emberlin J, Hardaker P, Collier C. Acute asthma epidemics, weather and pollen in England, 1987-1994// Eur Respir J.– 1998.-Vol11, N3.-P.694-701.
185.Tillie-Leblond I, Gosset P, Tonnel AB. Inflammatory events in severe acute asthma// Allergy 2005.-Vol60, N1.-P.23-9.
186.Tan WC. Viruses in asthma exacerbations// Curr Opin Pulm Med.– 2005.-Vol 11, N1.-P. 21-26.
187.Calhoun WJ. Nocturnal asthma// Chest.– 2003.-Vol 123, N3 Suppl.-P.399S-405S.
188.Bumbacea D, Campbell D, Nguyen L, Carr D, Barnes PJ, Robinson D, et al. Parameters associated with persistent airflow obstruction in chronic severe asthma// Eur Respir J.– 2004.-Vol 24, N1.-P.122-8.
189.Wenzel S. Mechanisms of severe asthma// Clin Exp Allergy.– 2003.-Vol 33, N12.-P.1622-1628.
190.Thomson NC, Chaudhuri R, Livingston E. Asthma and cigarette smoking// Eur Respir J.– 2004.-Vol 24, N5.-P.822-833.
191.А.Г.Чучалин. Бронхиальная астма. Агар, 1997. Бронхиальная астма у взрослых. Атопический дерматит. Под редакцией А.Г.Чучалина. Атмосфера, 2002.
192.Dominguez Ortega J, Leon F, Martinez Alonso JC, et al: Fluorocytometric analysis of induced sputum cells in an asthmatic population. J Investig Allergol Clin Immunol 2004; 14:108-113.
193.Gelder CM, Thomas PS, Yates DH, et al: Cytokine expression in normal, atopic, and asthmatic subjects using the combination of sputum induction and the polymerase chain reaction. Thorax 1995; 50:1033-1037.
194.Dupont LJ, Demedts MG, Verleden GM: Prospective evaluation of the validity of exhaled nitric oxide for the diagnosis of asthma. Chest 123:751-756, 2003.
195.Jatakanon A, Uasuf C, Maziak W, et al: Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 160:1532-1539, 1999.
196.А.Г.Чучалин. Бронхиальная астма. Агар, 1997. Бронхиальная астма у взрослых. Атопический дерматит. Под редакцией А.Г.Чучалина. Атмосфера, 2002.
197.Бронхиальная астма у взрослых. Атопический дерматит. Под редакцией А.Г.Чучалина. Атмосфера, 2002.
198.Глобальная стратегия лечения и профилактики бронхиальной астмы. Пер. с англ. яз. Под ред. А.Г.Чучалина. Атмосфера, 2007.
199.Lange P, Parner J, Vestbo J, et al: A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 339:1194-1200, 1998.
200.Woodruff PW, Khashayar R, Lazarus SC, et al: Relationship between airway inflammation, hyper-responsiveness and obstruction in asthma. J Allergy Clin Immunol 108:753-758, 2001.
201.Bennett WD, Brown JS, Zeman KL, et al: Targeting delivery of aerosols to different lung regions. J Aerosol Med 2002; 15:179-188.
202.Weber EJ, Levitt MA, Covington JK, Gambrioli E: Effect of continuously nebulized ipratropium bromide plus albuterol on emergency department length of stay and hospital admission rates in patients with acute bronchospasm: A randomized, controlled trial. Chest 1999; 115:937-944.
203.Barnes PJ: Efficacy of inhaled corticosteroids in asthma. J Allergy Clin Immunol 1998; 102:531-538.
204.Adcock IM, Ito K: Molecular mechanisms of corticosteroid actions. Monaldi Arch Chest Dis 2000; 55:256-266.
205.Boushey HA: Relationship of asthma severity to fatalities. In: Sheffer AL, ed. Fatal Asthma, New York: Marcel Dekker; 1998:363-385.
206.NAEPP : Executive Summary of the NAEPP Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma: Update on Selected Topics, Bethesda, MD, NIH, 2002.
207.Toogood JH, Baskerville J, Jennings B, et al: Bioequivalent doses of budesonide and prednisone in moderate and severe asthma. J Allergy Clin Immunol 1989; 84:688-700.
208.Szefler S, Weiss S, Tonascia J: Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 2000; 343:1054-1063.
209.Agertoft L, Pedersen S: Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med 2000; 343:1064-1069.
210.Devillier P, Baccard N, Advenier C: Leukotrienes, leukotriene receptor antagonists and leukotriene synthesis inhibitors in asthma: an update. Part I. Synthesis, receptors and role of leukotrienes in asthma. Pharmacol Res 1999; 40:3-13.
211.Ducharme FM: Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: Systematic review of current evidence. BMJ 2003; 326:621.
212.Wechsler ME, Finn D, Gunawardena D, et al: Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest 2000; 117:708-713.
213.Barnes PJ: Theophylline: new perspectives for an old drug. Am J Respir Crit Care Med 2003; 167:813-818.
214.Ito K, Lim S, Caramori G, et al: A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci USA 2002; 99:8921-8926.
215.Leung DY, Sampson HA, Yunginger JW, et al: Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 2003; 348:986-993.
216.Boushey HA: New and exploratory therapies for asthma. Chest 2003; 123(Suppl 3):439S-445S.
217.Simon HU, Grotzer M, Nikolaizik WH, et al: High altitude climate therapy reduces peripheral blood T lymphocyte activation, eosinophilia, and bronchial obstruction in children with house-dust mite allergic asthma. Pediatr Pulmonol 1994; 17:304-311.
218.Platts-Mills TAE, Mitchell EB, Nock P, et al: Reduction of bronchial hyperreactivity during prolonged allergen avoidance. Lancet 1982; 2:675-678.
219.Bjornsdottir US, Jakobinudottir S, Runarsdottir V, Juliusson S: The effect of reducing levels of cat allergen (Fel d 1) on clinical symptoms in patients with cat allergy. Ann Allergy Asthma Immunol 2003; 91:189-194.
220.Woodcock A, Forster L, Matthews E, et al: Control of exposure to mite allergen and allergen-impermeable bed covers for adults with asthma. N Engl J Med 2003; 349:225-236.
221.Campbell D, DeKruyff RH, Umetsu DT: Allergen immunotherapy: Novel approaches in the management of allergic diseases and asthma. Clin Immunol 2000; 97:193-202.
222.Tighe H, Takabayashi K, Schwartz D, et al: Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol 106:124-134, 2000.
223.Cox G, Miller JD, McWilliams A, et al: Bronchial thermoplasty for asthma. Am J Respir Crit Care Med 173:965-969, 2006.
224.Rowe BH, Bota GW, Fabris L, Therrien SA: Inhaled budesonide in addition to oral corticosteroids to prevent asthma relapse following discharge from the emergency department: A randomized controlled trial. JAMA 1999; 281:2119-2126.
225.Edmonds ML, Camargo Jr CA, Brenner BE, Rowe BH: Replacement of oral corticosteroids with inhaled corticosteroids in the treatment of acute asthma following emergency department discharge: A meta-analysis. Chest 2002; 121:1798-1805.
226.National Institutes of Health/National Heart Lung and Blood Institute (NHLBI): Global Initiative for Asthma: Global Strategy for Asthma Management and Prevention; NHLBI/WHO Workshop Report March 1993. NIH Publication No. 95 – 3659, Bethesda, MD, National Heart, Lung, and Blood Institute, 1995.
227.National Heart, Lung, and Blood Institute : Guidelines for the Diagnosis and Management of Asthma. National Asthma Education and Prevention Program. Vol 2, No. 7, Bethesda, MD: NHLBI, NIH; 1997:1.8 – 9.
228.Greening AP, Ind PW, Northfield M, Shaw G: Treatment of adult asthmatic patients symptomatic on low dose inhaled corticosteroids: A comparison of the addition of salmeterol to existing inhaled corticosteroid therapy, with increasing the dose of inhaled corticosteroids. Lancet 1994; 344:219-224.
229.Rand CS, Wise RA, Nides M, et al: Metered-dose inhaler adherence in a clinical trial. Am Rev Respir Dis 1992; 146:1559-1564.
230.Liou A, Grubb JR, Schechtman KB, Hamilos DL: Causative and contributive factors to asthma severity and patterns of medication use in patients seeking specialized asthma care. Chest 2003; 124:1781-1788.
231.Slavin RG: Asthma and sinusitis. J Allergy Clin Immunol 90:534-537, 1992.
232.Harding SM, Richter JE: The role of gastroesophageal reflux in chronic cough and asthma. Chest 1997; 111:1389-1402.
233.Szefler SJ, Eigen H: Budesonide inhalation suspension: A nebulized corticosteroid for persistent asthma. J Allergy Clin Immunol 2002; 109:730-742.
234.Bousquet J, Ben-Joseph R, Messonnier M, et al: A meta-analysis of the dose-response relationship of inhaled corticosteroids in adolescents and adults with mild to moderate persistent asthma. Clin Ther 2002; 24:1-20.
235.McIvor RA, Pizzichini E, Turner MO, et al: Potential masking effects of salmeterol on airway infalmmation in asthma. Am J Respir Crit Care Med 1998; 158:924-930.
236.Lazarus SC, Boushey HA, Fahy JV, et al: Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: A randomized controlled trial. JAMA 2001; 285:2583-2593.
237.O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al: Low dose inhaled budesonide and formoterol in mild persistent asthma: The OPTIMA randomized trial. Am J Respir Crit Care Med 2001; 164:1392-1397.
238.Pauwels RA, Lofdahl C-G, Postma DS, et al: Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337:1405-1411.
239.Nelson HS, Busse WW, Kerwin E, et al: Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 2000; 106:1088-1095.
240.Leung DY, Szefler SJ: New insights into steroid resistant asthma. Pediatr Allergy Immunol 1998; 9:3-12.
241.Soler M, Matz J, Townley R, et al: The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18:254-261.
242.Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma Update on Selected Topics-2002. J Allergy Clin Immunol 110:S141-S219, 2002.
document:
$pr:
version: 01-2007.1
codepage: windows-1251
type: klinrek
id: kli2793843
: 08.4. МУКОВИСЦИДОЗ
meta:
author:
fio[ru]: Е.Л. Амелина, М.В. Самсонова
codes:
next:
type: dklinrek
code: III.III
Муковисцидоз (МВ), или кистозный фиброз поджелудочной железы, – моногенное заболевание, обусловленное системной дисфункцией экзокринных желез. Клинически оно проявляется прогрессирующей инфекцией и обструкцией дыхательных путей, экзокринной недостаточностью поджелудочной железы, нарушением процессов пищеварения и всасывания в кишечнике, холестатическими осложнениями, а также снижением репродуктивной функции у мужчин в связи с недоразвитием или отсутствием семявыносящих протоков.
